Khaled Elsayad1, Jan Kriz2, Heinrich Seegenschmiedt3, Detlef Imhoff4, Reinhard Heyd5, Hans Theodor Eich2, Oliver Micke6. 1. Department of Radiotherapy and Radiation Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany. Khaled.elsayad@uni-muenster.de. 2. Department of Radiotherapy and Radiation Oncology, University Hospital Muenster, Albert-Schweitzer-Campus 1, Building A1, 48149, Muenster, Germany. 3. Radiotherapy Center Hamburg, Hamburg, Germany. 4. Department of Radiotherapy and Radiation Oncology, Goethe University of Frankfurt, Frankfurt, Germany. 5. Department of Radiotherapy and Radiation Oncology, Community Hospital Offenbach, Offenbach am Main, Germany. 6. Department of Radiotherapy and Radiation Oncology, Franziskus Hospital Bielefeld, Bielefeld, Germany.
Abstract
BACKGROUND: Aneurysmal bone cysts (ABC) are rapidly growing benign osseous lesions composed of blood-filled channels separated by fibrous septa. Since the value of external beam radiotherapy (EBRT) for ABC has not been well defined, the German Cooperative Group on Radiotherapy for Benign Diseases performed the national register study described herein. PATIENTS AND METHODS: Five German institutions collected data regarding clinical features, treatment concepts, and outcome for patients with ABC who had been referred for local EBRT over the past 30 years. RESULTS: Between 1990 and 2015, 10 patients with ABC were irradiated (5 female/5 male). Median age was 23 years (range 14-40 years). Involved sites were: spine (n = 3), sacrum/pelvis (n = 2), shoulder/scapula (n = 2), humerus (n = 1), femur (n = 1), and radius (n = 1). The median EBRT total and fractional doses were 28 Gy (range 5-40 Gy) and 2 Gy (range 1-2 Gy), respectively. Median follow-up was 65 months (range 12-358 months). Persistent pain relief was achieved for all patients. However, long-term follow-up response data were only available for 7/10 patients. All 7 patients exhibited a radiological response and experienced no recurrent disease activity or pain during follow-up. Acute and late radiogenic toxicities ≥ grade 3 and secondary malignancies were also not observed. CONCLUSION: Primary or adjuvant EBRT seems to be an effective and safe treatment option for persistent or recurrent ABC. Fractionated doses below 30 Gy may be recommended.
BACKGROUND:Aneurysmal bone cysts (ABC) are rapidly growing benign osseous lesions composed of blood-filled channels separated by fibrous septa. Since the value of external beam radiotherapy (EBRT) for ABC has not been well defined, the German Cooperative Group on Radiotherapy for Benign Diseases performed the national register study described herein. PATIENTS AND METHODS: Five German institutions collected data regarding clinical features, treatment concepts, and outcome for patients with ABC who had been referred for local EBRT over the past 30 years. RESULTS: Between 1990 and 2015, 10 patients with ABC were irradiated (5 female/5 male). Median age was 23 years (range 14-40 years). Involved sites were: spine (n = 3), sacrum/pelvis (n = 2), shoulder/scapula (n = 2), humerus (n = 1), femur (n = 1), and radius (n = 1). The median EBRT total and fractional doses were 28 Gy (range 5-40 Gy) and 2 Gy (range 1-2 Gy), respectively. Median follow-up was 65 months (range 12-358 months). Persistent pain relief was achieved for all patients. However, long-term follow-up response data were only available for 7/10 patients. All 7 patients exhibited a radiological response and experienced no recurrent disease activity or pain during follow-up. Acute and late radiogenic toxicities ≥ grade 3 and secondary malignancies were also not observed. CONCLUSION: Primary or adjuvant EBRT seems to be an effective and safe treatment option for persistent or recurrent ABC. Fractionated doses below 30 Gy may be recommended.
Entities:
Keywords:
Bone neoplasms; Chromosome aberrations; Fracture; Pain; Toxicity
Authors: William M Mendenhall; Robert A Zlotecki; C Parker Gibbs; John D Reith; Mark T Scarborough; Nancy Price Mendenhall Journal: Am J Clin Oncol Date: 2006-06 Impact factor: 2.339
Authors: Stephanie R McKeown; Paul Hatfield; Robin J D Prestwich; Richard E Shaffer; Roger E Taylor Journal: Br J Radiol Date: 2015-10-14 Impact factor: 3.039
Authors: S J Feigenberg; R B Marcus; R A Zlotecki; M T Scarborough; B H Berrey; W F Enneking Journal: Int J Radiat Oncol Biol Phys Date: 2001-04-01 Impact factor: 7.038
Authors: Jan Kriz; Hans Theodor Eich; Frank Bruns; Reinhard Heyd; Ulrich Schäfer; Uwe Haverkamp; Jens Büntzel; Heinrich Seegenschmiedt; Oliver Micke Journal: Radiat Oncol Date: 2013-10-09 Impact factor: 3.481
Authors: Jonas A Strohm; Peter C Strohm; Jan Kühle; Hagen Schmal; Jörn Zwingmann Journal: Eur J Trauma Emerg Surg Date: 2022-08-21 Impact factor: 2.374